Nephrocare Health Services Limited
Healthcare›Healthcare›Healthcare Services›Healthcare Service Provider
Key metrics
Price as of 2026-07-20
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2025 | Mar 2026 |
|---|---|---|
| Sales | 260 Cr | 266 Cr |
| Operating expenses (approx.) | 196 Cr | 200 Cr |
| EBITDA | 64 Cr | 65 Cr |
| OPM % | 24.7% | 24.6% |
| Other income | 3 Cr | 12 Cr |
| Interest | 6 Cr | 3 Cr |
| Depreciation | 22 Cr | 26 Cr |
| Profit before tax | 36 Cr | 36 Cr |
| Tax % | 11.3% | 7.8% |
| Net profit | 32 Cr | 30 Cr |
| EPS (₹) | ₹3.43 | ₹3.03 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 999 Cr | Sign in for TTM |
| Operating expenses (approx.) | 747 Cr | Sign in for TTM |
| EBITDA | 251 Cr | Sign in for TTM |
| OPM % | 25.2% | Sign in for TTM |
| Other income | 25 Cr | Sign in for TTM |
| Interest | 60 Cr | Sign in for TTM |
| Depreciation | 91 Cr | Sign in for TTM |
| Profit before tax | 101 Cr | Sign in for TTM |
| Tax % | 20.5% | Sign in for TTM |
| Net profit | 77 Cr | Sign in for TTM |
| EPS (₹) | ₹8.48 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 20 Cr |
| Reserves | 1,096 Cr |
| Borrowings | 35 Cr |
| Other liabilities | 320 Cr |
| Total liabilities | 1,471 Cr |
| Fixed assets (net) | 396 Cr |
| CWIP | 6 Cr |
| Investments | 178 Cr |
| Other assets | 839 Cr |
| Total assets | 1,471 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 233 Cr |
| Cash from investing | -410 Cr |
| Cash from financing | 157 Cr |
| Net cash flow | -2 Cr |
| Free cash flow (OCF − Capex) | 114 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 14.0% |
| ROE % | 6.9% |
| Debtor days | — |
| Inventory days | 53 |
| Days payable | — |
| Cash conversion cycle | 53 |
| Debt / equity | 0.03 |
| Current ratio | 2.80 |
| Net debt / EBITDA | -0.36 |
Compare with peers
Loading peers…